| Identification | Back Directory | [Name]
Idarubicin | [CAS]
58957-92-9 | [Synonyms]
DMDR
4-DMD
IMI-30
IDAMYCIN
IDARUBICIN
nsc-256439
IDARUBICIN HCL
IMI-30：NSC-256439
4-demethoxy-daunomyci
4-demethoxydaunomycin
Demethoxydaunorubicin
Idarubicin HCL(BICINS)
1-Demethoxydaunorubicin
4-demethoxydaunorubicin
4-Demethoxy-daunorubicin
11-trihydroxy-(7s-cis)-alpha-l-lyxo-hexopyranosyl)oxy)-
7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-12-naphthacenedione
(7S,9S)-9-Acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S)-9-Acetyl-7β-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9β,11-trihydroxy-5,12-naphthacenedione
(7S,9S)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione
(7S-cis)-9-Acetyl-7-[(3-amincr2，3，6-trideoxy-α-L-lyxohexopyranosyl)oxy]-7，8，9，10-tetrahydro-6，9，11-trihydroxy-5，12-naphthacenedione
5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S,9S)-
5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S,9S)-
5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)-
(7S-CIS)-9-ACETYL-7-[(3-AMINO-2,3,6-TRIDEOXY-ALPHA-L-LYXO-HEXOPYRANOSYL)OXY]-7,8,9,10-TETRAHYDRO-6,9,11-TRIHYDROXY-5,12-NAPHTHACENEDIONE | [EINECS(EC#)]
1806241-263-5 | [Molecular Formula]
C26H27NO9 | [MDL Number]
MFCD00897212 | [MOL File]
58957-92-9.mol | [Molecular Weight]
497.5 |
| Chemical Properties | Back Directory | [Boiling point ]
589.46°C (rough estimate) | [density ]
1.3477 (rough estimate) | [refractive index ]
1.6000 (estimate) | [storage temp. ]
2-8°C
| [form ]
solid
| [pka]
pKa 4.73± 0.21 (Uncertain) |
| Hazard Information | Back Directory | [Uses]
Antineoplastic. | [Definition]
ChEBI: Idarubicin is a monosaccharide derivative, an anthracycline antibiotic and a deoxy hexoside. It derives from a hydride of a tetracene. | [Indications]
Idarubicin (Idamycin) differs from its parent compound,
daunorubicin, by the absence of the methoxy
group in the anthracycline ring structure. Its mechanisms
of action and resistance are similar to those of
doxorubicin and daunorubicin; however, it is more
lipophilic and more potent than these other anthracyclines.
Idarubicin undergoes extensive hepatic metabolism
and biliary excretion. Adverse reactions of idarubicin
are similar to those of its congeners. |
|
|